Underlined terms can be clicked for more information.
Tarlatamab is a type of drug called a bispecific T-cell engager, or BiTE® molecule, that has two key parts: a part that attaches to your T-cells, a type of immune cell, and a part that attaches to the cancer cells.
Tarlatamab is a type of immunotherapy that works differently than standard chemotherapy. It is designed to help the body's immune cells find, attach to, and attack cancer cells.
For patients with extensive-stage SCLC receiving their first course of treatment. Patients with prior limited-stage SCLC may qualify.
For patients with limited-stage SCLC who have completed chemotherapy and radiation therapy without progression.